Roy S. Herbst
   HOME

TheInfoList



OR:

Roy S. Herbst (born January 16, 1963) is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of
Medical Oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...
, and Associate Director for
Translational Research Translational research (also called translation research, translational science, or, when the context is clear, simply translation) is research aimed at translating (converting) results in basic research into results that directly benefit humans. ...
at
Yale Cancer Center Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer". It is one of a network of 51 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI).Curr ...
and
Yale School of Medicine The Yale School of Medicine is the graduate medical school at Yale University, a private research university in New Haven, Connecticut. It was founded in 1810 as the Medical Institution of Yale College and formally opened in 1813. The primary te ...
in New Haven, Connecticut.


Education

After earning a BS and MS degree from
Yale University Yale University is a Private university, private research university in New Haven, Connecticut. Established in 1701 as the Collegiate School, it is the List of Colonial Colleges, third-oldest institution of higher education in the United Sta ...
, Herbst earned his
Doctor of Medicine Doctor of Medicine (abbreviated M.D., from the Latin ''Medicinae Doctor'') is a medical degree, the meaning of which varies between different jurisdictions. In the United States, and some other countries, the M.D. denotes a professional degree. T ...
at
Cornell University Medical College The Joan & Sanford I. Weill Medical College of Cornell University is Cornell University's biomedical research unit and medical school located in Upper East Side, Manhattan, New York City, New York. Weill Cornell Medicine is affiliated with New ...
and his PhD in Molecular Cell Biology at
The Rockefeller University The Rockefeller University is a private biomedical research and graduate-only university in New York City, New York. It focuses primarily on the biological and medical sciences and provides doctoral and postdoctoral education. It is classified ...
in New York City. His clinical fellowships in Medicine and Hematology were completed at the
Dana–Farber Cancer Institute Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana–Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by ...
and Brigham and Women's Hospital, respectively. Subsequently, he completed a MS degree in Clinical Translational Research at
Harvard University Harvard University is a private Ivy League research university in Cambridge, Massachusetts. Founded in 1636 as Harvard College and named for its first benefactor, the Puritan clergyman John Harvard, it is the oldest institution of high ...
in Cambridge, Massachusetts. Herbst was the Barnhart Distinguished Professor and Chief of the Section of
Thoracic The thorax or chest is a part of the anatomy of humans, mammals, and other tetrapod animals located between the neck and the abdomen. In insects, crustaceans, and the extinct trilobites, the thorax is one of the three main divisions of the crea ...
Medical Oncology in the Department of Thoracic/Head & Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Starting in 2011, Herbst has been the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital.


Career


Clinical research

Herbst's early career focused on the clinical development of novel targeted agents for the treatment of
lung cancer Lung cancer, also known as lung carcinoma (since about 98–99% of all lung cancers are carcinomas), is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. Lung carcinomas derive from transformed, malign ...
, including the early phase development of therapies targeting the
epidermal growth factor receptor The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor rece ...
and
vascular endothelial growth factor Vascular endothelial growth factor (VEGF, ), originally known as vascular permeability factor (VPF), is a signal protein produced by many cells that stimulates the formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, ...
receptor signaling pathways for the treatment of lung cancer. Herbst designed and led the national Biomarker-integrated Approaches of Targeted Therapy for Lung cancer Elimination (BATTLE) clinical trial. He is the national principal investigator of clinical trial "Lung-MAP". Herbst and his colleagues at Yale did early research on the presence of the immune checkpoint protein
PD-L1 Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the ''CD274'' gene. Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protei ...
in tumors that may dictate response to the
immunotherapy Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as ''activation immunotherapies,'' while immunotherap ...
atezolizumab Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellula ...
. This work earned their team the Herbert Pardes Clinical Research Achievement Award from the Clinical Research Forum, its top award in the US for 2015. Herbst leads a lung cancer-focused
National Cancer Institute The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. ...
specialized programs of research excellence (SPORE) grant at Yale, investigating novel immune based therapies, new methods to combat treatment resistance and understanding mechanisms of brain metastasis. From 2015 to 2019, he served as Yale's representative Principal Investigator of the
Stand Up To Cancer Stand Up to Cancer (SU2C) is a charitable program of the Entertainment Industry Foundation (EIF). SU2C aims to raise significant funds for translational cancer research through online and televised efforts. Central to the program is a telethon tha ...
-American Cancer Society Lung Cancer Dream Team.


Professional service

Herbst holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research and the
American College of Physicians The American College of Physicians (ACP) is a national organization of internists, who specialize in the diagnosis, treatment, and care of adults.Sokanu "What is an Internist?" Retrieved October 20, 2014 With 161,000 members, ACP is the largest ...
.


Select publications

*"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial" *"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2" *"Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer" *"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck" *"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial"


Awards

* 2010, Waun Ki Hong Award for Excellence in Team Science * 2016 Paul A. Bunn, Jr. Scientific Award * 2019, Asclepios Award * 2020, AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy


References


External links


National Cancer Institute’s Translational Research Program (TRP), Specialized Programs of Research Excellence in Lung Cancer
{{DEFAULTSORT:Herbst, Roy S. 1963 births Living people American oncologists Yale School of Medicine faculty Yale University alumni Cornell University alumni Rockefeller University alumni Harvard University alumni